{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:08:55Z","timestamp":1760148535330,"version":"build-2065373602"},"reference-count":47,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Beh\u00e7et\u2019s syndrome (BS) is a rare systemic vasculitis characterized by different clinical manifestations. As no specific laboratory tests exist, the diagnosis relies on clinical criteria, and the differential diagnosis with other inflammatory diseases can be challenging. Indeed, in a relatively small proportion of patients, BS symptoms include only mucocutaneous, articular, gastrointestinal, and non-typical ocular manifestations, which are frequently found also in psoriatic arthritis (PsA). We investigate the ability of serum interleukin (IL)-36\u03b1\u2014a pro-inflammatory cytokine involved in cutaneous and articular inflammatory diseases\u2014to differentiate BS from PsA. A cross-sectional study was performed on 90 patients with BS, 80 with PsA and 80 healthy controls. Significantly lower IL-36\u03b1 concentrations were found in patients with BS as compared to PsA, although in both groups IL-36\u03b1 was significantly increased compared to healthy controls. An empirical cut-off of 420.6 pg\/mL displayed a specificity of 0.93, with a sensitivity of 0.70 (AUC 0.82) in discriminating PsA from BS. This cut-off displayed a good diagnostic performance also in BS patients lacking highly specific BS manifestations. Our results indicate that IL-36\u03b1 might be involved in the pathogenesis of both BS and PsA, and might be a candidate biomarker to support the differential diagnosis of BS.<\/jats:p>","DOI":"10.3390\/ijms24108817","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T02:37:51Z","timestamp":1684204671000},"page":"8817","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Serum Interleukin-36 \u03b1 as a Candidate Biomarker to Distinguish Beh\u00e7et\u2019s Syndrome and Psoriatic Arthritis"],"prefix":"10.3390","volume":"24","author":[{"given":"Alessandra","family":"Bettiol","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Firenze, 50134 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Fagni","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3\u2014Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nuremberg and Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Mattioli","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Firenze, 50134 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3998-3561","authenticated-orcid":false,"given":"Giacomo","family":"Bagni","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Firenze, 50134 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4196-3527","authenticated-orcid":false,"given":"Gianfranco","family":"Vitiello","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Firenze, 50134 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Grassi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Firenze, 50134 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2565-6220","authenticated-orcid":false,"given":"Chiara","family":"Della Bella","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Firenze, 50134 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0792-2326","authenticated-orcid":false,"given":"Marisa","family":"Benagiano","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Firenze, 50134 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Troilo","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Firenze, 50134 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna Stella","family":"Holownia","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Firenze, 50134 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8310-7820","authenticated-orcid":false,"given":"David","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3\u2014Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nuremberg and Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6172-1851","authenticated-orcid":false,"given":"Flavia Rita","family":"Argento","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Firenze, 50134 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurgen","family":"Sota","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Beh\u00e7et\u2019s Disease Clinic, University of Siena, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[{"name":"Ophthalmology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2593-5908","authenticated-orcid":false,"given":"Matteo","family":"Becatti","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Firenze, 50134 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-1581","authenticated-orcid":false,"given":"Claudia","family":"Fiorillo","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Firenze, 50134 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3\u2014Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nuremberg and Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-9566","authenticated-orcid":false,"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Emergency and Organs Transplantation (DETO), University of Bari, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":false,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Beh\u00e7et\u2019s Disease Clinic, University of Siena, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Prisco","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Firenze, 50134 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Silvestri","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Firenze, 50134 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Firenze, 50134 Firenze, Italy"},{"name":"Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Clayton, VIC 3168, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario Milco","family":"D\u2019Elios","sequence":"additional","affiliation":[{"name":"Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3389\/fimmu.2019.02830","article-title":"Treating the Different Phenotypes of Behcet\u2019s Syndrome","volume":"10","author":"Bettiol","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"iii101","DOI":"10.1093\/rheumatology\/kez626","article-title":"Behcet: The syndrome","volume":"59","author":"Bettiol","year":"2020","journal-title":"Rheumatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41584-022-00880-7","article-title":"Vascular Behcet syndrome: From pathogenesis to treatment","volume":"19","author":"Bettiol","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kiafar, M., Faezi, S.T., Kasaeian, A., Baghdadi, A., Kakaei, S., Mousavi, S.A., Nejadhosseinian, M., Shahram, F., Ghodsi, S.Z., and Shams, H. (2021). Diagnosis of Behcet\u2019s disease: Clinical characteristics, diagnostic criteria, and differential diagnoses. BMC Rheumatol., 5.","DOI":"10.1186\/s41927-020-00172-1"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1046\/j.1365-4362.2003.01741.x","article-title":"Evaluation of clinical findings according to sex in 2313 Turkish patients with Behcet\u2019s disease","volume":"42","author":"Tursen","year":"2003","journal-title":"Int. J. Dermatol."},{"key":"ref_6","first-page":"808","article-title":"2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s11739-019-02046-y","article-title":"Phenotypes in Behcet\u2019s syndrome","volume":"14","author":"Seyahi","year":"2019","journal-title":"Intern. Emerg. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"International Team for the Revision of the International Criteria for Behcet\u2019s, D (2014). The International Criteria for Behcet\u2019s Disease (ICBD): A collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J. Eur. Acad. Dermatol. Venereol., 28, 338\u2013347.","DOI":"10.1111\/jdv.12107"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jaut.2018.09.002","article-title":"Efficacy of the anti-IL 17 secukinumab in refractory Behcet\u2019s syndrome: A preliminary study","volume":"97","author":"Bettiol","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/annrheumdis-2020-217108","article-title":"Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behcet\u2019s phenotype: A multicentre study","volume":"79","author":"Fagni","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3899\/jrheum.090218","article-title":"Psoriatic arthritis sine psoriasis","volume":"83","author":"Olivieri","year":"2009","journal-title":"J. Rheumatol. Suppl."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10067-014-2652-9","article-title":"Extra-articular manifestations in psoriatic arthritis patients","volume":"34","author":"Peluso","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1038\/s41598-021-81972-4","article-title":"Association of Behcet disease with psoriasis and psoriatic arthritis","volume":"11","author":"Hahn","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"737079","DOI":"10.3389\/fmed.2021.737079","article-title":"Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk","volume":"8","author":"Novelli","year":"2021","journal-title":"Front. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"151956","DOI":"10.1016\/j.semarthrit.2022.151956","article-title":"Immunopathogenesis of Behcet\u2019s disease and treatment modalities","volume":"52","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1074\/mcp.M116.061002","article-title":"Identification of Novel Biomarkers for Behcet Disease Diagnosis Using Human Proteome Microarray Approach","volume":"16","author":"Hu","year":"2017","journal-title":"Mol. Cell. Proteom."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102763","DOI":"10.1016\/j.autrev.2021.102763","article-title":"Interleukin 1alpha: A comprehensive review on the role of IL-1alpha in the pathogenesis and treatment of autoimmune and inflammatory diseases","volume":"20","author":"Cavalli","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/ar1946","article-title":"The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes","volume":"8","author":"Magne","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cei.12761","article-title":"Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn\u2019s disease","volume":"184","author":"Boutet","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.autrev.2011.12.005","article-title":"Cytokines and Behcet\u2019s disease","volume":"11","author":"Zhou","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","article-title":"Efficacy and safety profile of anti-interleukin-1 treatment in Behcet\u2019s disease: A multicenter retrospective study","volume":"35","author":"Emmi","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet\u2019s disease-related uveitis: A multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/09273948.2018.1511810","article-title":"The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behcet\u2019s Disease","volume":"28","author":"Fabiani","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00296-019-04259-y","article-title":"The right place of interleukin-1 inhibitors in the treatment of Behcet\u2019s syndrome: A systematic review","volume":"39","author":"Bettiol","year":"2019","journal-title":"Rheumatol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1038\/jid.2015.289","article-title":"Unprocessed Interleukin-36alpha Regulates Psoriasis-Like Skin Inflammation in Cooperation With Interleukin-1","volume":"135","author":"Milora","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6756138","DOI":"10.1155\/2016\/6756138","article-title":"Imiquimod Treatment Causes Systemic Disease in Mice Resembling Generalized Pustular Psoriasis in an IL-1 and IL-36 Dependent Manner","volume":"2016","author":"Alvarez","year":"2016","journal-title":"Mediators Inflamm."},{"key":"ref_29","first-page":"179","article-title":"Evaluating Serum Levels of IL-33, IL-36, IL-37 and Gene Expression of IL-37 in Patients with Psoriasis Vulgaris","volume":"17","author":"Sehat","year":"2018","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/rheumatology\/kez358","article-title":"Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis","volume":"59","author":"Boutet","year":"2020","journal-title":"Rheumatology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Boutet, M.A., Nerviani, A., and Pitzalis, C. (2019). IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: A Comprehensive Review of Their Therapeutic Potential. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061257"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"42594","DOI":"10.1074\/jbc.M111.267922","article-title":"Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity","volume":"286","author":"Towne","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"24880","DOI":"10.1038\/srep24880","article-title":"Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist","volume":"6","author":"Macleod","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/cei.13664","article-title":"Neutrophil-mediated mechanisms of damage and in-vitro protective effect of colchicine in non-vascular Behcet\u2019s syndrome","volume":"206","author":"Bettiol","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"911347","DOI":"10.3389\/fimmu.2022.911347","article-title":"NETosis in Psoriatic Arthritis: Serum MPO-DNA Complex Level Correlates With Its Disease Activity","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIRCULATIONAHA.115.017738","article-title":"Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Behcet Disease","volume":"133","author":"Becatti","year":"2016","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/cei.13243","article-title":"Behcet\u2019s syndrome as a tool to dissect the mechanisms of thrombo-inflammation: Clinical and pathogenetic aspects","volume":"195","author":"Becatti","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"ref_38","first-page":"152","article-title":"Anakinra for resistant Behcet uveitis: Why not?","volume":"31","author":"Emmi","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1038\/s41598-019-45626-w","article-title":"Small Molecule IL-36gamma Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis","volume":"9","author":"Todorovic","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1517\/13543776.2014.881473","article-title":"Anti-IL-36R antibodies, potentially useful for the treatment of psoriasis: A patent evaluation of WO2013074569","volume":"24","author":"Wolf","year":"2014","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/gutjnl-2015-310374","article-title":"IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo","volume":"66","author":"Scheibe","year":"2017","journal-title":"Gut"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4049\/jimmunol.1501312","article-title":"Cutting Edge: IL-36 Receptor Promotes Resolution of Intestinal Damage","volume":"196","author":"Harusato","year":"2016","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"156974","DOI":"10.1136\/annrheumdis-2012-202264","article-title":"The novel cytokine interleukin-36\u03b1 is expressed in psoriatic and rheumatoid arthritis synovium","volume":"72","author":"Frey","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1074\/jbc.275.2.1169","article-title":"Four new members expand the interleukin-1 superfamily","volume":"275","author":"Smith","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fcell.2019.00317","article-title":"Function and Regulation of IL-36 Signaling in Inflammatory Diseases and Cancer Development","volume":"7","author":"Queen","year":"2019","journal-title":"Front. Cell. Dev. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"716760","DOI":"10.3389\/fcell.2021.716760","article-title":"Changes in the Gut Microbiome Contribute to the Development of Behcet\u2019s Disease via Adjuvant Effects","volume":"9","author":"Wang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Liu, Y., Fan, Q.Y., Zhang, N., Mi, L.Y., Zhao, X., and Xu, K. (2023). Characterisation of circulating endothelial microparticles in Beh\u00e7et\u2019s disease: New markers of chronic endothelial damage?. Clin. Exp. Rheumatol.","DOI":"10.55563\/clinexprheumatol\/kceh9s"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/10\/8817\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:35:47Z","timestamp":1760124947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/10\/8817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["ijms24108817"],"URL":"https:\/\/doi.org\/10.3390\/ijms24108817","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2023,5,16]]}}}